Actively Recruiting
Phase 1 Study to Evaluate Safety and Immune Response of the HDT-321 RNA Vaccine Against Crimean-Congo Hemorrhagic Fever in Healthy Adults Aged 18 to 64
Led by HDT Bio · Updated on 2025-07-28
48
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and immune response of an investigational vaccine called HDT-321 for protection against Crimean-Congo hemorrhagic fever virus CCHFV in healthy adults aged 18 to 64 years. This first-in-human, open-label study involves testing three different dosage levels and comparing single or two-dose regimens to better understand the vaccines effects and safety profile. The study includes four groups of 12 participants each, receiving varying doses of HDT-321 10 micrograms with two doses, 25 micrograms with two doses, 50 micrograms with one dose, and 50 micrograms with two doses. Participants receive the vaccine by intramuscular injection on day 1, with some groups receiving a second dose on day 29. The study progresses carefully with initial safety monitoring of smaller sentinel groups before enrolling the full group at each dose level. Participants will attend multiple clinic visits and phone calls for safety checks and blood sample collection, including memory aid completion for 7 days after each injection to track side effects. Researchers will monitor adverse events locally and systemically for up to 28 days after each dose, serious events throughout the study lasting up to about 13 months, and will evaluate immune responses until day 57. The study aims to collect detailed safety and immune response data to better understand HDT-321.
CONDITIONS
Brief Title
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
Research Team
J
James Keary
A
Aude Frevol
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here